<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">



EUC.jpg

 

 

 

WINNER: 

Polyphor

EU Capital Market Transaction of the Year

The Award

This award recognises a European company that has successfully completed a significant or transformational IPO in the period between 1 September 2017 and 1 September 2018.

Judges paid particular attention to:

  • Amount of funds raised.
  • Process/speed/allocation fulfilment of securing significant new funds.
  • Level/reputation of new investor(s) attracted.
  • Post-finance allocation/use of proceeds.
  • Level of value creation/value realisation from raise.

Company Description  

Polyphor was founded in 1996 and is a clinical stage biopharmaceutical company based in Allschwil, Switzerland, near Basel. It focuses on the development of macrocycle drugs that address antibiotic resistance and improve therapy outcomes in cancer.

Our lead drug candidates

Murepavadin (POL7080)
A precision Outer Membrane Protein Targeting Antibiotic (OMPTA) against Pseudomonas aeruginosa

Balixafortide (POL6326)
An antagonist of the chemokine receptor CXCR4 for combination treatment in oncology

POL6014 –  Outlicensed to Santhera on 14.02.2018
An inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases

DOWNLOAD THE 2018 WINNERS